(lp0
S'AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV ... PR Newswire  - Apr 13, 2017 REDWOOD CITY, Calif., April 13, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe&nbsp;...AcelRx Pharmaceuticals Inc.  Moves Lower on Volume Spike for April 12 - Equities.comAcelRx Pharma  Announces Publication of Manuscripts Analyzing IV ... - StreetInsider.com'
p1
aS'AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results ... PR Newswire  - Apr 6, 2017 REDWOOD CITY, Calif., April 6, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe&nbsp;...'
p2
aS"Why AcelRx Pharmaceuticals Inc. Is Crashing Motley Fool - Mar 10, 2015 What's happening: Shares in AcelRx Pharmaceuticals  continued their decline today, falling by as much as 10% after the company reported disappointing fourth quarter results. The drop follows yesterday's 37% collapse on news that the FDA&nbsp;...AcelRx Pharmaceuticals  Stock Extends Losses Today as Jefferies Downgrades - TheStreet.com"
p3
aS"AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced ... PR Newswire  - Aug 15, 2016 REDWOOD CITY, Calif., Aug. 15, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe&nbsp;..."
p4
aS"AcelRx Pharmaceuticals, Inc.  Sees Unusual Volume Mid-Session The Herald - 15 hours ago Investors are on alert as AcelRx Pharmaceuticals, Inc. 's stock is experiencing unusual volume during today's trading.AcelRx Pharmaceuticals  At $2.65 Forms Bottom, Service International ... - Key GazetteAcelRx Pharmaceuticals  Reaches $2.75 After 9.00% Down Move, Secor ... - UtahHerald.com"
p5
aS'AcelRx Pharmaceuticals: Blockbuster Potential Makes This $2 Stock A Strong Buy ... Seeking Alpha - Jan 10, 2017 AcelRx Pharmaceuticals shares appear deeply undervalued and could be poised for a short squeeze rally. This company has financial strength and two strong pipeline candidates, including a potential &quot;blockbuster&quot; that could get FDA approval in 2017.'
p6
aS'AcelRx Pharmaceuticals, Inc. to Present at The MicroCap Conference on April ... Yahoo Finance - Mar 16, 2017 The MicroCap Conference will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4, at 7:00AM, and will last until the evening.'
p7
aS'AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy PR Newswire  - Oct 1, 2015 REDWOOD CITY, Calif., Oct. 1, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today&nbsp;...'
p8
aS'European Medicines Agency Begins Evaluation of Marketing Application for ... PR Newswire  - Mar 28, 2017 REDWOOD CITY, Calif., March 28, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe&nbsp;...'
p9
aS'AcelRx Initiates Phase 3 Study of Zalviso in Patients with Moderate-to-Severe ... PR Newswire  - Sep 27, 2016 REDWOOD CITY, Calif., Sept. 27, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe&nbsp;...Stock Update : AcelRx Pharmaceuticals Inc Initiates Phase 3 Study ... - Smarter AnalystAcelRx launches late-stage study of pain med device Zalviso in hospital setting - Seeking Alpha'
p10
a.